Lilianne Kim

1.3k total citations
25 papers, 853 citations indexed

About

Lilianne Kim is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Lilianne Kim has authored 25 papers receiving a total of 853 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 14 papers in Hematology and 9 papers in Immunology. Recurrent topics in Lilianne Kim's work include Rheumatoid Arthritis Research and Therapies (14 papers), Autoimmune and Inflammatory Disorders Research (14 papers) and Spondyloarthritis Studies and Treatments (10 papers). Lilianne Kim is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Autoimmune and Inflammatory Disorders Research (14 papers) and Spondyloarthritis Studies and Treatments (10 papers). Lilianne Kim collaborates with scholars based in United States, Belgium and Canada. Lilianne Kim's co-authors include Cris S. Constantinescu, Lloyd H. Kasper, Benjamin M. Segal, Aparna Raychaudhuri, Kim Hung Lo, Alan M. Mendelsohn, Jocelyn H. Leu, Elizabeth C. Hsia, Diane D. Harrison and Zhenhua Xu and has published in prestigious journals such as Gastroenterology, The Lancet Neurology and Annals of the Rheumatic Diseases.

In The Last Decade

Lilianne Kim

24 papers receiving 822 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lilianne Kim United States	11	492	458	264	222	100	25	853
Maria Luisa Lombardi Italy	17	213 0.4×	281 0.6×	127 0.5×	469 2.1×	212 2.1×	38	832
Erdwine Klinker Germany	13	186 0.4×	142 0.3×	71 0.3×	396 1.8×	169 1.7×	21	672
Румен Стоилов Bulgaria	12	223 0.5×	287 0.6×	112 0.4×	45 0.2×	65 0.7×	45	542
Ahjoku Amadi‐Obi United States	6	589 1.2×	251 0.5×	73 0.3×	74 0.3×	25 0.3×	6	991
J. Woody Germany	6	320 0.7×	274 0.6×	99 0.4×	228 1.0×	18 0.2×	7	763
Mirko Scarsi Italy	12	218 0.4×	181 0.4×	38 0.1×	86 0.4×	36 0.4×	18	454
Ilaria Biagini Italy	9	313 0.6×	159 0.3×	77 0.3×	46 0.2×	20 0.2×	27	606
Emma Ross United Kingdom	7	272 0.6×	293 0.6×	136 0.5×	32 0.1×	42 0.4×	8	729
William A. Figgett Australia	11	442 0.9×	182 0.4×	41 0.2×	78 0.4×	51 0.5×	18	768
Sokratis A. Apostolidis United States	15	696 1.4×	391 0.9×	51 0.2×	62 0.3×	25 0.3×	19	1.0k

Countries citing papers authored by Lilianne Kim

Since Specialization

Citations

This map shows the geographic impact of Lilianne Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lilianne Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lilianne Kim more than expected).

Fields of papers citing papers by Lilianne Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lilianne Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lilianne Kim. The network helps show where Lilianne Kim may publish in the future.

Co-authorship network of co-authors of Lilianne Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Lilianne Kim. A scholar is included among the top collaborators of Lilianne Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lilianne Kim. Lilianne Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Turner, Dan, Joel R. Rosh, Stanley A. Cohen, et al.. (2024). Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results. Journal of Pediatric Gastroenterology and Nutrition. 79(2). 315–324. 5 indexed citations

Rosh, Joel R., Dan Turner, Jeffrey S. Hyams, et al.. (2024). Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease. Journal of Crohn s and Colitis. 18(8). 1250–1260.

Anders, Hans‐Joachim, Tak Mao Chan, Jorge Sánchez‐Guerrero, et al.. (2024). Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study. Lara D. Veeken. 64(5). 2731–2740. 2 indexed citations

Ogdie, Alexis, Jessica A. Walsh, Soumya D. Chakravarty, et al.. (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clinical Rheumatology. 40(9). 3667–3677. 3 indexed citations

Reveille, John D., Atul Deodhar, Akgun Ince, et al.. (2020). Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial. Value in Health. 23(10). 1281–1285. 6 indexed citations

Mease, Philip J., M. Elaine Husni, Soumya D. Chakravarty, et al.. (2020). Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study. ACR Open Rheumatology. 2(11). 640–647. 9 indexed citations

Husni, M. Elaine, Arthur Kavanaugh, Eric K. H. Chan, et al.. (2020). Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial. Value in Health. 23(10). 1286–1291. 4 indexed citations

Reveille, John D., Mark C. Hwang, Abhijeet Danve, et al.. (2020). The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology. 40(4). 1331–1341. 8 indexed citations

Husni, M. Elaine, Arthur Kavanaugh, Frederick T. Murphy, et al.. (2019). Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis. Arthritis Care & Research. 72(6). 806–813. 16 indexed citations

10.

Reveille, John D., Atul Deodhar, Paul H. Caldron, et al.. (2019). Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study. The Journal of Rheumatology. 46(10). 1277–1283. 17 indexed citations

11.

Husni, M. Elaine, Philip J. Mease, Soumya D. Chakravarty, et al.. (2019). AB0754 CLINICALLY MEANINGFUL IMPROVEMENT IN SKIN AND NAIL PSORIASIS IN BIO-NAÏVE ACTIVE PSORIATIC ARTHRITIS PATIENTS TREATED WITH INTRAVENOUS GOLIMUMAB: RESULTS THROUGH WEEK 52 FROM A PHASE-3 STUDY. Annals of the Rheumatic Diseases. 78. 1843–1844. 2 indexed citations

12.

Deodhar, Atul, John D. Reveille, Diane D. Harrison, et al.. (2017). Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study. The Journal of Rheumatology. 45(3). 341–348. 43 indexed citations

13.

Telesco, Shannon, Linda E. Greenbaum, Hongyan Zhang, et al.. (2017). Prediction of Non-Response to Anti-Tnf Therapy in Ulcerative Colitis: Implications for Patient Stratification for IBD Trials and Novel Treatment Paradigms. Gastroenterology. 152(5). S984–S985. 1 indexed citations

14.

Bingham, Clifton O., Alan M. Mendelsohn, Lilianne Kim, et al.. (2015). Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial. Arthritis Care & Research. 67(12). 1627–1636. 15 indexed citations

15.

Bingham, Clifton O., Michael E. Weinblatt, Chenglong Han, et al.. (2014). The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial. The Journal of Rheumatology. 41(6). 1067–1076. 15 indexed citations

16.

Weinblatt, Michael E., René Westhovens, Alan M. Mendelsohn, et al.. (2013). Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Annals of the Rheumatic Diseases. 73(12). 2152–2159. 33 indexed citations

17.

Weinblatt, Michael E., Clifton O. Bingham, Alan M. Mendelsohn, et al.. (2012). Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Annals of the Rheumatic Diseases. 72(3). 381–389. 82 indexed citations

18.

Taylor, Peter C., Christopher T. Ritchlin, Alan M. Mendelsohn, et al.. (2011). Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab. The Journal of Rheumatology. 38(12). 2572–2580. 10 indexed citations

19.

Kremer, Joel M., Christopher T. Ritchlin, Alan M. Mendelsohn, et al.. (2010). Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty‐eight–week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled study. Arthritis & Rheumatism. 62(4). 917–928. 105 indexed citations

20.

Segal, Benjamin M., et al.. (2008). Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet Neurology. 7(9). 796–804. 369 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact